1	Autoantibody-Driven Monocyte Dysfunction in Post-COVID Syndrome with Myalgic				
2	Encephalomyelitis/Chronic Fatigue Syndrome				
3					
4	Alexander Hackel ^{1#*} and Franziska Sotzny ^{#2} , Elise Mennenga ¹ , Harald Heidecke ³ ,				
5	Kai Schulze-Foster ³ , Konstantinos Fourlakis ¹ , Susanne Lüders ¹ ,				
6	Hanna Grasshoff ¹ , Kerstin Rubarth ^{4‡} , Frank Konietschke ⁴ , Tanja Lange ¹ ,				
7	Carmen Scheibenbogen ² , Reza Akbarzadeh ^{1‡} , Gabriela Riemekasten ^{1‡}				
8					
9	¹ Department of Rheumatology and Clinical Immunology, University of Lübeck, Lübeck,				
10	Germany				
11	² Institute for Medical Immunology, Charité–Universitätsmedizin Berlin, Berlin, Germany				
12	Corporate Member of Freie Universität Berlin and Humboldt Universität Zu Berlin, Berlin,				
13	Germany				
14	³ CellTrend GmbH, Luckenwalde, Germany				
15	⁴ Institute for Biometry and Clinical Epidemiology, Charite–Universitätsmedizin Berlin, Berlin,				
16	German				
17					
18	*Corresponding author				
19	[‡] Senior author				
20	# Shared first author				
21					
22	Correspondance:				
23	Dr. Alexander Hackel				
24	Department of Rheumatology and Clinical Immunology, University of Lübeck				
25	Address: Ratzeburger Allee 160, 23538 Lübeck				
26	Telephone: +49 0451 500 45201				
27	Email: alexandermaximilian.hackel@uksh.de				
28					
29	Keywords: Autoantibodies, Post-COVID Syndrom, ME/CFS, Monocyte-Derived Cytokines,				
30	Biomarker				
31					

Running title: IgG-induced cytokine response of monocytes in PCS 32

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

All rights reserved. No reuse allowed without permission.

33 Abstract

Post-COVID syndrome (PCS) has emerged as a significant health concern with persisting 34 symptoms. A subset of PCS patients develops severe myalgic encephalomyelitis/chronic 35 36 fatigue syndrome (pcME/CFS). Dysregulated autoantibodies (AABs) have been implicated in 37 PCS, contributing to immune dysregulation, impairment of autonomous nerve and vascular function. As recently shown in autoimmune diseases, IgG fractions translate disease-specific 38 39 pathways into various cells. Therefore, we asked whether IgG fractions from PCS patients could be applied in-vitro to identify specific cytokine responses for PCS patients without (nPCS) 40 and with pcME/CSF. To assess this, we have stimulated monocyte cell lines with IgG fractions 41 42 from PCS patients. Our findings reveal distinct cytokine responses induced by patient derived 43 AABs which are suggested in vascular and immune dysfunction. In contrast to nPCS, pcME/CSF AABs induced enhanced neurotrophic responses, characterized by significant 44 cytokine correlations involving brain-derived neurotrophic factor (BDNF), glial cell-derived 45 neurotrophic factor (GDNF) and tumor necrosis factor superfamily member 14 (LIGHT). 46 Further, AAB-induced cytokine levels correlate with clinical symptoms. This study emphasizes 47 a contribution of AABs in PCS, in mitigating long-term immune dysregulation, and a need for 48 therapies modulating IgG-induced signaling pathways. 49

All rights reserved. No reuse allowed without permission.

50 Introduction

Post-COVID syndrome (PCS) has become a major public health concern, affecting 10–20% 51 of individuals after SARS-CoV-2 infection. Symptoms persist for a minimum of two months and 52 53 often severely impair daily functioning. [1-3] Among these patients, a subgroup fulfills the 54 Canadian Consensus Criteria (CCC) for diagnosis of myalgic encephalomyelitis/chronic 55 fatigue syndrome (ME/CFS) [4-6]. The clinical overlap between PCS and ME/CFS highlights 56 the shared but poorly understood mechanisms underlying these conditions. Emerging evidence implicates a complex interplay of immune dysregulation, endothelial dysfunction, and 57 vascular anomalies in PCS, which may differ from these in pcME/CFS [7-9]. Functional 58 autoantibodies (AABs) have been identified as significant contributors to immune dysregulation 59 60 in both acute and post-viral syndromes [10]. For example, AABs against renin-angiotensin system (RAS)-related proteins, including angiotensin-converting enzyme 2 (ACE2) and 61 62 angiotensin type-1 receptor (AT1R), correlate with disease severity in acute COVID-19 and vascular dysfunction in PCS [11]. Our studies suggest a contribution of specific AABs in 63 inflammatory conditions. As an example, AT1R AABs induced skin and lung inflammation as 64 well as endothelial apoptosis [12, 13]. In ME/CFS, disease-specific alterations in the G-protein 65 coupled receptor (GPCR) AAB network have been associated with key symptoms such as 66 fatigue, muscle pain, and neurocognitive impairments [14, 15]. Similar disruptions in PCS 67 suggest a shared mechanism of immune-mediated dysfunction, with GPCR AABs potentially 68 69 modulating both inflammatory and neurotrophic pathogenic alterations. Intriguingly, in PCS, 70 AABs against adrenergic receptors were identified as key markers distinguishing symptom 71 severity, emphasizing their contribution to vascular dysfunction and endothelial impairment [16]. Similarly, in PCS, AABs targeting vasoregulatory and immune-modulatory proteins have 72 73 been linked to chronic vascular inflammation and immune dysregulation.

74 Monocytes, as pivotal responders of innate immunity, are emerging as key mediators in the immunopathogenesis of PCS and pcME/CFS. In viral infections, monocytes act as first-line 75 76 effectors, contributing to immune defense and tissue repair. However, their dysregulation can lead to pathological inflammation and tissue damage, as seen in macrophage activation 77 syndrome during severe COVID-19 [17, 18]. Monocyte-driven responses, particularly through 78 79 secreted cytokines such as CCL18, are also implicated in fibrotic and neurodegenerative processes characteristic for autoimmune diseases such as systemic sclerosis, but also for 80 PCS [19]. As shown by our group, IgG fractions from patients with autoimmune diseases 81 82 induce a disease-specific protein pattern and pathways in monocytes [12]. The IgG-induced 83 secretome could thus serve as a biomarker for pathways present in their corresponding donor and as a diagnostic tool. To address this hypothesis, the current study investigates the role of 84 AAB-induced monocyte activation in PCS and pcME/CFS. By focusing on the monocyte 85 86 secretome, this research aims to elucidate whether known mechanisms in ME/CFS such as

inflammatory and neurodegenerative processes are induced by AABs, whether IgG-induced cytokines and proteins show associations with clinical findings, and whether the cytokine signature could be used as diagnostic tool. Our study represents the first comprehensive investigation into the interaction between AABs, monocyte activation, and disease pathophysiology in PCS and pcME/CFS, offering new insights into potential therapeutic

92 targets.

All rights reserved. No reuse allowed without permission.

93 Methods

94 Cohort characteristics

Female participants between 24 and 51 years were recruited at the Charité Fatigue Centre, 95 96 Berlin. Serum samples were collected from 24 PCS patients with persistent fatigue and 97 exercise intolerance following mild to moderate acute SARS-CoV-2 infection and from 12 age-matched healthy controls (HCs). 12 out of 24 PCS patients fulfilled the Canadian 98 99 Consensus Criteria (CCC) for diagnosis of ME/CFS (pcME/CFS), others were categorized as PCS none ME/CFS (nPCS), the PCS group includes both defined Subgroups. Most patients 100 had a disease duration >6 months, in two of 11 pcME/CFS patients, and in two of 13 PCS 101 102 patients with a disease duration < 6 months, the diagnosis was confirmed at month 6.

103 Detailed cohort information is displayed in **Table 1**. Disease and symptom severity were assessed by questionnaires: The functional disability was evaluated by Bell score, ranging 104 from 0 to 100 (with 100 for no restrictions) [20]. PEM severity was evaluated according to Cotler 105 et al., with scores ranging from 0 to 46 (no to frequent/severe PEM) [21]. The severity of the 106 key symptoms, fatigue, pain, and cognitive impairment was quantified using a Likert scale 107 (1 = no symptoms to 10 = severe symptoms). Fatigue was additionally evaluated using the 108 Chalder Fatigue Scale from 0 to 33 (no to heavy fatigue) [22]. Autonomic dysfunction was 109 assessed using the Composite Autonomic Symptom Score 31 (COMPASS-31), ranging from 110 0 to 100 (no to strongest impairment) [23]. Clinical data was collected and managed using 111 112 REDCap electronic data capture tools hosted at Charité University Medicine Berlin [24, 25]. 113 Whole blood samples from participants were allowed to clot at room temperature and then centrifuged at 2000 x g for 15 min at 4°C. The purified serum was stored at -80°C for further 114 analysis. SARS-CoV-2 Serology was performed at the Institute for Immunology at Charité 115 Universitätsmedizin Berlin using Anti-SARS-CoV-2 ELISA (IgG) according to manufacturer 116 protocol (Euroimmun Medizinische Labordiagnostika AG, Lübeck, Germany). This study was 117 approved the Ethics Committee of Charité Universitätsmedizin Berlin 118 by (EA2/067/20, EA2/066/20). The participants gave written informed consent. 119

Table 1: Clinical scorings and cohort characterization. Continuous variables were expressed
 as median and range. Univariate comparisons of study groups were done using the Kruskal–
 Wallis test (three groups) or the Mann-Whitney-U-Test (two groups). A two-tailed p-value of
 <0.05 was considered statistically significant. [n. a. = not assessed].

Cohort characterization	HC ¹	nPCS	pcME/CFS	p-value ²
Age [in years]	37 (24 - 51), n = 12	36 (27 - 50), n = 13	36 (28 - 51), n = 11	0.897
BMI	20.2 (20.2 - 20.2), n = 1	23.1 (18.4 - 34.8), n = 12	25.3 (15.4 - 40.8), n = 11	0.513
disease duration [years]	0.50 (0.35 - 0.88), n = 12	0.56 (0.36 - 1.03), n = 13	0.64 (0.42 - 1.99), n = 11	0.306
disease duration [months]	6.0 (4.2 - 10.6), n = 12	6.7 (4.4 - 12.4), n = 13	7.7 (5.1 - 23.9), n = 11	0.252

anti-NCAP-IgG	0.42 (0.00 - 1.44), n = 4	0.00 (0.00 - 3.99), n = 4	0.00 (0.00 - 7.36), n = 7	0.819
anti-Spike-IgG	3.9 (1.3 - 12.5), n = 12	5.8 (1.3 - 12.5), n = 12	6.7 (1.2 - 11.6), n = 9	>0.999
Cohort characterization				
Age [in years]	37 (24 - 51), n = 12	36 (27 - 50), n = 13	36 (28 - 51), n = 11	0.897
Clinical scorings	HC	nPCS	pcME/CFS ¹	p-value ²
Bell	N/A	50 (30 - 80), n = 13	30 (20 - 50), n = 11	0.012
PEM score	N/A	24.0 (21.0 - 32.0), n = 11	33.0 (25.0 - 44.0), n = 11	0.010
Role limitations due to physical health	N/A	0 (0 - 75), n = 13	0 (0 - 0), n = 11	0.027
Energy Fatigue	N/A	35 (5 - 55), n = 13	10 (0 - 55), n = 11	0.054
Emotional Wellbeing	N/A	68 (24 - 88), n = 13	64 (44 - 84), n = 11	0.930
Social Functioning	N/A	50 (12 - 100), n = 13	25 (0 - 75), n = 10	0.109
Pain	N/A	45 (10 - 78), n = 13	32 (0 - 55), n = 10	0.060
General health	N/A	38 (20 - 65), n = 12	30 (5 - 40), n = 11	0.045
Health Change	N/A	0 (0 - 25), n = 12	0 (0 - 75), n = 11	0.417
Physical Sum Scale	N/A	35 (25 - 43), n = 12	27 (10 - 34), n = 10	0.007
Psychical Sum Scale	N/A	38 (13 - 47), n = 12	31 (20 - 53), n = 10	0.722
Fatigue SY-1	N/A	6.00 (2.00 - 10.00), n = 13	8.00 (5.00 - 10.00), n = 11	0.088
Severity of Muscle Pain SY-6	N/A	5.00 (1.00 - 8.00), n = 13	7.00 (1.00 - 10.00), n = 11	0.519
Severity of Headache SY-7	N/A	6.50 (1.00 - 9.00), n = 12	4.00 (1.00 - 9.00), n = 11	0.106
Joint Paint SY-8	N/A	3.50 (1.00 - 8.00), n = 12	3.00 (1.00 - 10.00), n = 11	0.901
Fatigue Score	N/A	7.00 (2.25 - 8.50), n = 13	8.25 (5.25 - 10.00), n = 11	0.027
Cognitive Score	N/A	6.17 (1.67 - 7.67), n = 12	5.67 (3.00 - 7.00), n = 11	0.459
Immune Score	N/A	3.33 (1.00 - 8.00), n = 12	3.33 (1.67 - 7.67), n = 11	0.688
COMPASS-31 (total)	N/A	36 (2 - 51), n = 13	34 (10 - 70), n = 11	>0.999
-orthostatism	N/A	16 (0 - 32), n = 13	16 (0 - 40), n = 11	0.883
-vasomotor	N/A	0.00 (0.00 - 0.00), n = 13	0.00 (0.00 - 4.17), n = 11	0.023
-secremotor	N/A	6.4 (0.0 - 10.7), n = 13	4.3 (0.0 - 12.9), n = 11	>0.999
-gastrointestinal	N/A	6.2 (0.0 - 15.2), n = 13	7.1 (0.0 - 14.3), n = 11	0.954
-bladder	N/A	1.11 (0.00 - 4.44), n = 13	1.11 (0.00 - 2.22), n = 11	0.807
-pupillomotor	N/A	2.00 (0.33 - 3.00), n = 13	1.00 (0.00 - 3.67), n = 11	0.145

All rights reserved. No reuse allowed without permission.

IgG	N/A	11.67 (8.77 - 16.18), n	10.43 (6.08 - 13.56), n =	0.061
		= 11	11	
lgG1	N/A	6.56 (4.73 - 8.21), n = 11	5.56 (3.73 - 6.67), n = 8	0.020
lgG2	N/A	4.76 (2.75 - 5.67), n = 11	3.53 (1.80 - 5.86), n = 8	0.272
lgG3	N/A	0.49 (0.19 - 1.13), n = 11	0.38 (0.18 - 0.54), n = 8	0.351
lgG4	N/A	0.32 (0.20 - 1.25), n = 11	0.22 (0.14 - 0.84), n = 8	0.057

124

125 Culturing and Preparation of Cells

Human monocytic U937 cells (ACC-5, DSMZ-German Collection of Microorganisms and Cell Cultures GmbH) were cultured in VLE RPMI 1640 medium (Bio & Sell, #F1415) supplemented with 10% heat-inactivated fetal calf serum (Bio & Sell #FCS-ULE1415), 100 U/ml penicillin, and 100 μ g/ml streptomycin (BioWest #L0022). The cells were incubated under sterile conditions at 37 °C with 5% carbon dioxide in culture flasks. For stimulation experiments, U937 cells were seeded at a density of 2 × 10⁶ cells/ml one hour before stimulation in 24-well plates (Sarstedt, #83.3922500).

133

134 Isolation of Human IgG

Human IgG was isolated from the patient serum using affinity chromatography at room 135 temperature. Serum samples were diluted fourfold in binding buffer (20 mM Na2HPO4+20 mM 136 NaH2PO4, pH 7) and centrifuged at 10,000 x g for 10 minutes at 4 °C. The supernatant was 137 aspirated from below the lipid layer and transferred to a fresh tube. HiTrap protein G Sepharose 138 139 columns (Cytiva, Sweden, #17040401) were equilibrated with binding buffer, and the diluted 140 serum was passed through the columns. Unbound molecules were washed out, and bound 141 IgG was eluted using 100 mM glycine (pH 2.7). The eluate was immediately neutralized with 142 1 M TRIS buffer, then diluted with PBS (BioWest, #L0615) to 15 ml and passed through centrifugal filter units (Amicon, #UFC901024) at 3,000 g and 4 °C. After replenishing and re-143 centrifuging, the retentate, the IgG concentration was measured using Bradford's reagent 144 (BioRad #5000006) according to the manufacturer's instructions. 145

146

147 Stimulation of U937 Cells with IgG from Patients and Healthy Controls

148 For stimulation experiments, U937 cells were exposed to purified IgG from three groups: a) nPCS, b) pcME/CFS, and c) COVID-recovered HC. 6.67 µM IgG preparation was added to 149 150 the cells [13]. After stimulation for 24h, the cells were centrifuged, and the supernatants were 151 stored at -20 °C for cytokine analysis. The levels of cytokines in the supernatants were chips 152 analyzed using cvtokine antibody array glass (RayBiotech, Norcross, GA, USA, #AAH-CYT-G5-8). The array protocol was followed as per 153

the manufacturer's instructions: Non-specific binding sites on the chamber slides were blocked

using a blocking buffer. Following this, the supernatants were incubated on the slides with a

biotinylated antibody cocktail. After multiple washes, streptavidin-fluorochrome reagent HiLyte

Plus™ Fluor 555 was added. The slides were then laser-scanned at 532 nm using an Innoscan
 Microarray Scanner (Innopsys, France). Background signals were subtracted, and the signals
 were normalized to positive controls before further analysis using Agilent Scan Control

- 160 Software ver9.1.
- 161

154

162 Data Preparation

163 Data preparation was performed using the array manufacturer's batch correction tool available 164 at RayBiotech's online platform. Raw signals were first corrected for background by subtracting the median background intensities. Subsequently, signal normalization was performed. To 165 normalize distribution and stabilize variance, the data underwent log2 transformation. Further 166 processing of the data was performed using the limma package in R software to eliminate non-167 168 biological variance between different experimental batches. This additional step enhanced the reliability of subsequent statistical analyses, enabling the detection of meaningful biological 169 170 signals amidst technical variability.

171

172 Statistical Analysis

173 Descriptive Statistics were conducted to characterize the study groups, using medians and 174 ranges for numerical data due to the small sample size. For exploratory univariate analyses, 175 non-parametric tests were applied, including Kruskal-Wallis tests and Mann-Whitney U tests. Principal Component Analysis (PCA) was performed on the batch-corrected dataset to explore 176 177 variance structure and clustering among the PCS, pcME/CFS, nPCS, and HC groups. PCA plots provided a visual representation of the separation between groups, highlighting clustering 178 patterns. PCA visualizations were generated using the ggplot2 package in R. Linear Modeling 179 was conducted to identify cytokines with differential expression between groups using the 180 limma package. Comparisons included PCS vesus HC, pcME/CFS versus nPCS, pcME/CFS 181 versus HC, and nPCS versus HC. Volcano plots were generated to visualize these differential 182 183 expression patterns, highlighting cytokines with statistically significant fold changes, defined as an absolute log-fold change greater than one, with a significance level set at 10%, due to 184 the exploratory nature of the study. 185

186 **Correlation analysis** was performed to examine pairwise relationships between cytokines, as 187 well as between cytokines and clinical scores, as well as anti SARS-CoV2-Nukleocapsid 188 (NCAP) IgG and anti SRAS-CoV2-Spike Protein IgG utilizing Spearman's rank correlation 189 coefficient. This non-parametric approach was chosen to capture both linear and non-linear 190 associations, providing insights into co-regulatory mechanisms within the immune network.

191 Correlation matrices were generated separately for pcME/CFS, nPCS, and HC groups, allowing for the identification of unique interaction patterns within each study group. Heatmaps, 192 created by using the ggplot2 package, provided a detailed visual summary of immune 193 194 interactions in the three groups. Significant correlations are marked with [*] for $p \le 0.01$. The 195 classification of the correlation coefficient effect size is set as follows, values between 0 and 196 0.2 indicate no or a very small effect, from 0.2 up to 0.5 correspond to a small effect, while 197 values from 0.5 up to 0.8 signify a medium effect. Any value from 0.8 and above represents a 198 strong effect. All statistical analyses and visualizations were conducted in R (version 4.2.1) by using RStudio (version 7.1), leveraging specialized packages tailored for each analysis step. 199

200

201 Rational defining surrogate cytokine marker

202 Cytokines appearing in the volcano plots with an absolute log-fold change greater than one 203 and a corresponding p-value below 10%, or those identified through a Kruskal-Wallis test with 204 a p-value below 10%, were selected as relevant candidates for further analysis.

205

206 KEGG Analysis

Kyoto Encyclopedia of Genes and Genomes (KEGG) was implemented to understand disease pathogenesis through its detailed pathway maps and databases. For our study, surrogate cytokines with significant correlations, as shown in **Figure 3**, were used as input for KEGG pathway analysis (https://www.genome.jp/kegg) to identify biologically and clinically relevant pathways.

212

All rights reserved. No reuse allowed without permission.

214 Results

The IgG-induced secretome discovered differences in PCS groups and in response to viral proteins

217 After stimulation with purified IgG, the cytokine profiles of monocytic U937 cells were analyzed by a cytokine array comprising 80 different proteins. To measure AAB-induced cytokine 218 expression between HC and diseased cohorts, principal component analysis (PCA) was 219 220 employed to stratify high-dimensional data and to uncover distinct cytokine profiles, which could contribute to group separations. Study groups were matched for a similar age distribution 221 and disease duration (Table 1). The BMI was not different among the groups. Our data indicate 222 223 a distinct clustering pattern across the groups (Figure 1). When comparing HC to all PCS 224 patients, including those with and without ME/CFS, a clear separation between the two cohorts was identified (Figure 1A). Comparison of nPCS versus pcME/CFS demonstrated partially 225 overlapping clustering (Figure 1B), indicating shared immune dysregulation while also 226 capturing subgroup-specific immune patterns. PCS is characterized by an abnormal immune 227 response to SARS-CoV-2. To understand the differences in IgG-induced cytokine profiles 228 concerning specific antibodies against SARS-CoV-2 proteins, IgG-induced cytokines were 229 clustered according to the antibodies directed to SARS-CoV-2-spike and SARS CoV2- SARS-230 231 CoV2-NCAP. Here, only significantly upregulated cytokines were selected. Interestingly, SARS-CoV-2-specific antibodies did reveal the strongest correlations with IgG-induced 232 cytokines by applying HC-IgG. As examples, spike IgG antibody levels did positively correlate 233 234 with GRO-α (Growth-Regulated Oncogene Alpha: 0.72, р = 0.01), IL-7 (Interleukin 7; 0.68, p = 0.01), and IL-5 (Interleukin 5; 0.67, p = 0.02). Additionally, positive 235 correlations with antibody levels against SARS-CoV2-NCAP were shown with IGFBP-4 236 237 (Insulin-Like Growth Factor Binding Protein 4: 0.74, = 0.26), IL-4 р (Interleukin 4; 0.74, p = 0.26), and SCF (Stem Cell Factor; 0.74, p = 0.26), suggesting well-238 regulated immune communication (Figure 1C). In contrast, cytokine correlations with SARS-239 CoV-2 spike IgG were markedly absent in nPCS with only a positive correlation with NT-4 240 (0.59; p=) and a negative correlation with TGF- β 3 (Transforming Growth Factor Beta 3) levels 241 (-0.61, p = 0.04). In the pcME/CFS group (**Figure 1C**), strong negative correlations between 242 spike IgG titers and NAP-2 (-0.90, p = 0.00), MCP-3 (-0.81, p = 0.03), and MIP-3 α 243 (-0.75, p = 0.03) levels were detected as well as between SARS-CoV2-NCAP IgG ab levels 244 and MCP-3 levels (-0.81, p = 0.03). These data indicate changes in regulatory mechanisms 245 induced by SARS-CoV-2 and a disturbed immune response compared to HC 246 (Figure 1C, nPCS). 247

- 248
- 249
- 250

All rights reserved. No reuse allowed without permission.

251 nPCS and pcME/CFS AABs mediate distinct cytokine profiles compared to HC.

252 Volcano plots illustrate significant differences in the IgG-induced cytokine expression between patients and HC. Comparing PCS with HC (Figure 2A), several cytokines had exhibited 253 254 significant upregulation such as MIP-1d (Macrophage Inflammatory Protein-1d), PDGF-BB 255 (Platelet-Derived Growth Factor-BB), TGF- β 3, and SCF (Stem Cell Factor), all of which had 256 shown both a high log2 fold change and statistically significant p-values. These cytokines are 257 involved in inflammatory, fibrotic, and tissue repair pathways, suggesting persistent immune activation. Further, in PCS, PIGF (Placental Growth Factor), MCP-2 (Monocyte Chemotactic 258 Protein-2), and IL-4 have been also upregulated as markers for angiogenesis, monocyte 259 260 recruitment, and Th2-related anti-inflammatory responses. Thrombopoietin, a marker for 261 disruptions in coagulation, was modestly upregulated. The IgG-induced secretome also showed differences between pcME/CFS and nPCS (Figure 2B). Specifically, IL-1a 262 263 alpha), GRO- α (Growth-Regulated Oncogene alpha), and Eotaxin-3 (Interleukin-1 (Eosinophil Chemotactic Protein 3) revealed notable increases in expression in pcME/CFS. 264 265 The detailed comparison between nPCS or pcME/CFS with HC exhibited minor differences in the expression patterns (**Figure 2C** and **D**). MIP-1 δ , IL-4 and TGF- β 3, revealed comparable 266 upregulation in nPCS as well in pcME/CFS groups compared to HC, suggesting shared 267 268 features in PCS regardless of ME/CFS status. Interestingly, in the nPCS group compared to 269 HC, a downregulated cytokine levels of GRO- α , IL-5 and IL-7 were found (**Figure 2C**).

270

AAB-induced secretome identified distinct correlations between cytokines and pathways among the different groups.

Intra-cytokine correlations showed marked differences as illustrated in **Figure 3**. In HC, only a 273 few strong correlations such as between FGF-9 and MDC levels (r = 0.90; p < 0.001), between 274 Gro-a and IL-5 as well as IFN-g and TGF-b1 (both r = 0.84; p<0.001), (Figure 3A). Pathway 275 276 analysis for HC of the AAB-induced monocyte secretome (Figure 3B) revealed a minor number of cytokines involved in autoimmune or infectious disease-related pathways, 277 underscoring the homeostatic nature of HC cytokine interactions. In nPCS (Figure 3C), 278 AAB-induced monocyte secretomes reflected altered immune signaling, with strong positive 279 correlations between cytokine levels of IL-15 and IL-5 (r 0.99 p<0.001), GDNF and IGF-I 280 (r = 0.94; p<0.001), IL-15 and IL-7 (r = 0.94; p<0.001) and NAP-2 and PDGF-BB 281 (r = 0.90; p<0.001). Pathways associated with viral infections and rheumatoid arthritis were 282 found, alongside IL-17 signaling pathways. These pathways suggest an overlap between 283 284 pcME/CFS immune dysregulation and inflammatory responses commonly observed in viral and autoimmune conditions (Figure 3D). In pcME/CFS (Figure 3E), unique cytokine 285 286 correlations were found between IL-15 and TNF-b (r = 0.99; p<0.001), IFN-g and TGF-b1 287 (r = 0.97; p<0.001), FGF-9 and PIGF (r = 0.95; p<0.001) and FGF-9 and

All rights reserved. No reuse allowed without permission.

MIP-3a (r = 0.91; p<0.001). Pathway analysis of these cytokine networks (Figure 3F) revealed 288 strong functional enrichments in pathways associated with rheumatoid arthritis and 289 inflammatory bowel disease, cytokine signaling in viral infection. These findings suggest that 290 291 pcME/CFS-associated AABs drive immune networks with significant overlap to chronic 292 inflammatory and viral infection-related pathways. In both diseased groups, strong correlations 293 were found between IL-5 and IL-7 (nPCS, 0.95; p<0.001 / pcME/CFS, r = 0.99; p<0.001). 294 Also, moderate correlations in both groups were observed between BDNF (Brain-Derived Neurotrophic Factor) and LIGHT, (nPCS, r = 0.86; p<0.001; pcME/CFS r = 0.88; p<0.001). 295 Noteworthy, in both PCS groups (Figure 3D, F) significant fold enrichments were found for 296

297 RAS-signaling pathways. Cytokine-receptor interactions were found in all groups resembling 298 the nature of cytokine data submitted to KEGG analysis. In sum, the data underscore the 299 critical role of IgG-induced monocyte secretomes in driving disease-specific cytokine 300 interactions and signaling networks.

301

IgG-induced proteins correlate with distinct manifestations in nPCS and pcME/CFS.

303 To explore how IgG-driven cytokine responses may contribute to specific symptoms, 304 IgG-induced protein levels were compared with clinical data (Figure 4). In nPCS (Figure 4 A), moderate positive correlations were found between cytokine levels and symptom severity 305 (Bell score). Autonomic dysfunction assessed by the total Composite Symptom Score 306 307 (Compass-31 total), correlated significantly with Eotaxin levels (r = 0.60, p = 0.03), indicating 308 its role in exacerbating symptoms and eosinophil recruitment [26]. In more detail, the domain 309 bladder impairment (Compass-31) showed strong correlations with IGFBP-4 levels (r = 0.75, p < 0.001), PIGF (r = 0.69, p = 0.01), and MCP-2 levels (r = 0.63, p = 0.02), reflecting 310 311 the involvement of neuroprotective mechanisms, vascular inflammation, and monocyte recruitment in nPCS bladder symptoms [27-29]. Remarkably, severity of fatigue were positively 312 correlated with IL-4 levels (r = 0.66, p = 0.01), emphasizing Th2-mediated immune activation 313 [30] as well as with FGF-9 levels (r = 0.72, p = 0.01). Eotaxin levels were moderately correlated 314 with the degree autonomic dysfunction (r = 0.6, p = 0.03). In nPCS, gastrointestinal symptoms 315 (com gi) were negatively associated with RANTES levels (r = -0.79, p < 0.001) and NAP-2 316 317 levels (r = -0.68, p = 0.01), indicating the role of impaired monocyte chemotactic signaling in 318 eosinophil regulation [31].

In pcME/CFS (**Figure 4B**), unique cytokine correlations suggested heightened neuroinflammatory and immune dysregulation compared to nPCS. The levels of RANTES, involved in angiogenesis as well as in inflammation, were strongly correlated positively with both the Bell Disability Score (r = 0.72, p = 0.01) and bladder dysfunction (com_blad) (r = 0.71, p = 0.01) [32]. Correlations between the Immune Score and the levels of the neurotrophin NT4 (r = 0.68, p = 0.02) were observed. Interestingly, severity of fatigue was

All rights reserved. No reuse allowed without permission.

correlated with Thrombopoietin levels (r = 0.62, p = 0.04), implicating platelet activation in 325 fatigue and chronic inflammation [33]. Additionally, levels of IGFBP-4 (r = 0.61, p = 0.05), a 326 neuronal survival factor [27], was correlated positively with the severity of muscle pain. The 327 328 degree of cognitive dysfunctions was correlated negatively with GRO- α (r = -0.67, p = 0.02), 329 while IL-7 levels negatively correlated with muscle pain severity (r = -0.60, p = 0.05). The levels 330 of the chemokine MCP-2, found increased in PCS patients [29] and causing endothelial 331 impairment [34], was correlated particularly with orthostatic dysfunction (r = 0.68; p = 0.02) and 332 compass-31 (com total; r = 0.62, p = 0.05). In pcME/CFS, neuroinflammatory markers had shown stronger negative correlations compared to nPCS. IL-1 α correlated negatively with 333 severity of headache (r = -0.82, p < 0.001), suggesting its role in neuroinflammation linked to 334 335 headache symptoms. TGF-β1 also had shown negative correlations with headache severity (r = -0.62, p = 0.04), alterations of regulatory signaling in pcME/CFS [31]. 336

337

338 Discussion

In this study, we aimed to identify common and distinct IgG-driven immune mechanisms, by 339 stimulating monocytes, a supposed key cell in the response to virus infections, with IgG from 340 nPCS and pcME/CFS patients [13, 16, 35]. The observed differences in the responses to viral 341 proteins indicate disturbed immune response already present at the beginning of PCS. In 342 general, PCS patients exhibit distinct patterns of cytokine upregulation associated with immune 343 344 dysregulation, tissue repair, and chronic inflammation. In addition, key differences between 345 nPCS and pcME/CFS were identified, suggesting that IgG from pcME/CFS patients exhibit 346 more pronounced neurotrophic responses. IgG-induced cytokines exhibit strong correlations with clinical symptoms emphasizing similarities between IgG-induced pathways and those 347 present in the patients. The results of this study strongly indicate a contribution of AAB in the 348 pathogenesis of disease and provide important insights into the immune landscape of PCS. 349 The study highlights potential pathways involved in the persistence of symptoms and the 350 development of chronic fatigue-related conditions. 351

352

In pcME/CFS, AABs mediated strong inflammatory and neurotrophic cytokines indicating 353 354 immune and endothelial dysregulation. The significant upregulation of cytokines such as MIP-1d, PDGF-BB, and TGF- β 3 in PCS patients points to persistent immune dysregulation by 355 AABs months after the acute phase of SARS-CoV-2 infection. These proteins are implicated 356 357 in tissue repair and fibrosis, aligning with recent findings that suggest long-term tissue damage 358 and scarring may be prominent features of PCS [36]. The upregulation of PIGF further supports 359 the hypothesis of ongoing vascular and immune disturbances in PCS patients caused by dysregulation of the autoantibodiome. PIGF has been associated with vascular inflammation 360 361 and angiogenesis, both of which may contribute to chronic symptoms such as fatigue and

All rights reserved. No reuse allowed without permission.

shortness of breath observed in PCS patients [8]. The increased levels of IL-4 indicate a mixed immune response, where both pro-inflammatory and regulatory pathways are activated, may reflecting the complex nature of immune recovery in PCS. Moreover, the moderate upregulation of Thrombopoietin may suggest the involvement of platelet activation and coagulation pathways or a negative rebound causing thrombocytopenia, which have been implicated in both acute COVID-19 and long-COVID syndromes [33]. This could contribute to microvascular dysfunction, further exacerbating symptoms such as brain fog and fatigue.

By distinguishing the immune response to IgG between nPCS to pcME/CFS the upregulation 369 of IL-1α, GRO-α, and Eotaxin-3 in pcME/CFS patients aligns with previous studies that have 370 371 demonstrated immune dysregulation and heightened inflammation in ME/CFS compared to 372 nPCS groups. These cytokines are critical mediators of inflammation, which could contribute to the severe fatigue, post-exertional malaise, and other hallmark symptoms of ME/CFS [37]. 373 374 pcME/CFS-IgG triggered cytokine profile also reflects a shift toward a more chronic inflammatory state, GRO-a is linked to neutrophil activation and could be contributing to 375 chronic low-grade inflammation, while Eotaxin-3 suggests a potential role for eosinophils, 376 377 which are involved in allergic responses but also implicated in prolonged inflammatory states 378 [26, 38]. The relatively stable levels of TGF- β 1 in this cohort could point to a lack of sufficient 379 regulatory immune responses, which was partly observed in in-vitro experiments with PCS ME/CFS sera, where immune dysfunction persists, additionally resembled by sICAM-1, 380 381 IGFBPB-4 and cystatin-C [8]. These findings provide crucial insights into the very early 382 AAB-mediated processes occurring in PCS, particularly for patients with ME/CFS. The short-383 term nature of the experiments enables us to observe immune dysregulation at the onset of 384 the post-viral phase rather than long-term chronic responses.

385 The results of group specific cytokine correlations highlight distinct cytokine and growth factor 386 interactions in nPCS and pcME/CFS, shedding light on immune mechanisms underlying 387 symptom severity and disease progression. In both groups, while strongest correlations were 388 observed in pcME/CFS, for cytokines such as IL-5, IL-7, IL-15, and TNF-β, reflecting enhanced inflammatory and immune dysregulation. IL-15, associated with disease severity in COVID-19 389 [39] and TNF- β , a key marker uniquely elevated in ME/CFS after exercise[40], point to chronic 390 immune dysregulation and post-exertional inflammation, characteristic of pcME/CFS. These 391 392 findings suggest a sustained and amplified immune response compared to pcME/CFS. Growth factors such as FGF-9 and PIGF also exhibited stronger associations in pcME/CFS. FGF-9, 393 394 documented in movement disorders and ME/CFS, plays a role in tissue repair and is implicated 395 in pulmonary fibrosis [41], while PIGF is linked to angiogenesis and increased after acute exercise [42]. Together with pathway correlations with autoimmune diseases and 396 397 RAS-signaling, the results indicate angiogenic and fibrotic dysregulations, contributing to 398 tissue remodeling and symptom chronicity in pcME/CFS. These results underscore the

All rights reserved. No reuse allowed without permission.

importance of cytokines and growth factors induced by patient IgG in both the severity and
 progression
 of
 PCS.

401

402 The comparative analysis of the AAB-induced secretome revealed distinct immune pathways 403 underlying symptom manifestations in nPCS and pcME/CFS. These findings emphasize the 404 central role of immune dysregulation in driving fatigue, cognitive dysfunction, and organ-405 specific symptoms, highlighting the differing contributions of pro-inflammatory and 406 neuroprotective cytokines in these conditions. In nPCS, immune dysregulation was linked to symptom severity, with cytokines such as Eotaxin and IGFBP-4 prominently associated with 407 408 overall symptom burden and bladder dysfunction, respectively. Eotaxin, involved in eosinophil 409 recruitment and monocyte-driven inflammation, correlated positively with symptom severity, reflecting its role in immune-mediated exacerbation [31]. IGFBP-4, recognized for its 410 411 neuroprotective properties, showed a strong positive correlation with bladder dysfunction, 412 suggesting a compensatory response to immune-mediated damage in bladder tissues [27]. Thrombopoietin was negatively associated with post-exertional malaise (PEM), linking platelet 413 activation to vascular repair and immune recovery processes [33]. Similarly, RANTES and 414 NAP-2 exhibited negative correlations with gastrointestinal symptoms, reflecting impaired 415 416 chemotactic signaling and vascular regulation [31, 43]. The pcME/CFS demonstrated 417 heightened immune dysregulation and stronger associations with neuroinflammatory and 418 neuroprotective pathways. RANTES emerged as a dual mediator, positively correlating with 419 bladder dysfunction but better physical function (high Bell score), suggesting its involvement 420 in tissue repair and neuroimmune pathways specific to severe ME/CFS [32]. In fibromyalgia 421 syndrome, where muscle pain and bladder issues coexist, the association of IGFBP-4 with 422 muscle pain points to shared inflammatory pathways [44]. These findings highlight a neuroimmune axis driven by monocytes in response to AABs in both pain and autonomic 423 dysfunction. Noteworthy, bladder function did not correlate with the age of pcME/CFS patients. 424 Neurotrophic factors such as NT4 and PDGF-BB were positively correlated with immune 425 426 scores, which may indicate compensatory responses to ongoing neuroinflammation and tissue damage, both effectors promote survival of different immune cells [31, 45]. Fatigue in 427 428 pcME/CFS showed nuanced cytokine interactions. While IL-4 and MCP-2 were positively associated with fatigue, TGF- β 1 exhibited a negative correlation, reflecting its protective role 429 in regulating immune-driven fatigue [31, 46]. Intriguingly, MCP-2 upregulation is well described 430 431 in PCS patients, hypothesizing a key role of AAB-mediated monocytic response in PCS 432 pathogenesis [29]. Neuroinflammation was evident through negative correlations between cognitive function and cytokines such as Eotaxin and GRO-α, emphasizing the impact of 433 434 chronic inflammation on cognitive impairment [26, 27].

This study demonstrated IgG-induced cytokine signatures in an in vitro assay correlate more 435 pronounced with disease-specific symptoms compared to direct serum AAB measurements or 436 437 analyses of specific antibodies, such as β^2 -adrenergic receptor antibodies in ME/CFS [14, 16]. 438 These findings suggest that IgG-induced cytokine responses provide a more accurate 439 assessment of pathogenic potential. An in vitro diagnostic developed in parallel by the Clinic 440 for Rheumatology and Clinical Immunology (University Clinic Schleswig-Holstein; placeholder 441 (EP25150270.4) further validated these results, showing a sensitivity of 92% and specificity of 83% in distinguishing PCS patients from HC, and for the first time differentiating nPCS from 442 PCME/CFS patients. This approach highlights its potential for precise diagnosis and disease 443 444 prognosis.

445 Conclusion

446 The findings from this study suggest that the immune exhaustion observed in monocytes stimulated by IgG from nPCS and pcME/CFS patients could be driven by chronic activation 447 through dysregulated AABs. This has been observed in other chronic inflammatory conditions, 448 where persistent immune stimulation, like viral infections, lead to immune cell exhaustion and 449 450 endothelial impairment [47-49]. Thus, AABs may maintain a state of chronic immune activation, 451 which, over time, results in monocyte dysfunction and dedifferentiation, mirroring processes seen in autoimmune diseases and chronic infections [50, 51], subsequently contributing to 452 immune exhaustion and causing long-term symptoms observed in PCS with ME/CFS. 453 454

All rights reserved. No reuse allowed without permission.

456 **References**

- Davis, H.E., et al., *Characterizing long COVID in an international cohort: 7 months of symptoms and their impact.* eClinicalMedicine, 2021. 38: p. 101019.
- 459 2. Xie, Y., B. Bowe, and Z. Al-Aly, *Burdens of post-acute sequelae of COVID-19 by severity of acute*460 *infection, demographics and health status.* Nat Commun, 2021. **12**(1): p. 6571.
- 461 3. Logue, J.K., et al., Sequelae in Adults at 6 Months After COVID-19 Infection. JAMA Netw Open,
 462 2021. 4(2): p. e210830.
- 463 4. Kedor, C., et al., A prospective observational study of post-COVID-19 chronic fatigue syndrome
 464 following the first pandemic wave in Germany and biomarkers associated with symptom
 465 severity. Nat Commun, 2022. 13(1): p. 5104.
- 466 5. Nacul, L., et al., European Network on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
 467 (EUROMENE): Expert Consensus on the Diagnosis, Service Provision, and Care of People with
 468 ME/CFS in Europe. Medicina (Kaunas), 2021. 57(5).
- 469 6. Bonilla, H., et al., *Myalgic Encephalomyelitis/Chronic Fatigue Syndrome is common in post-*470 *acute sequelae of SARS-CoV-2 infection (PASC): Results from a post-COVID-19 multidisciplinary*471 *clinic.* Front Neurol, 2023. 14: p. 1090747.
- 472 7. Mejia-Renteria, H., et al., *In-vivo evidence of systemic endothelial vascular dysfunction in*473 *COVID-19.* Int J Cardiol, 2021. 345: p. 153-155.
- 474 8. Flaskamp, L., et al., Serum of Post-COVID-19 Syndrome Patients with or without ME/CFS
 475 Differentially Affects Endothelial Cell Function In Vitro. Cells, 2022. 11(15).
- 476 9. Haffke, M., et al., Endothelial dysfunction and altered endothelial biomarkers in patients with
 477 post-COVID-19 syndrome and chronic fatigue syndrome (ME/CFS). J Transl Med, 2022. 20(1):
 478 p. 138.
- 479 10. Wang, E.Y., et al., *Diverse functional autoantibodies in patients with COVID-19.* Nature, 2021.
 480 595(7866): p. 283-288.
- 481 11. Rodriguez-Perez, A.I., et al., *Autoantibodies against ACE2 and angiotensin type-1 receptors* 482 *increase severity of COVID-19.* J Autoimmun, 2021. 122: p. 102683.
- 48312.Cabral-Marques, O., et al., GPCR-specific autoantibody signatures are associated with484physiological and pathological immune homeostasis. Nat Commun, 2018. **9**(1): p. 5224.
- Yue, X., et al., *Induced antibodies directed to the angiotensin receptor type 1 provoke skin and lung inflammation, dermal fibrosis and act species overarching.* Ann Rheum Dis, 2022. 81(9):
 p. 1281-1289.
- 48814.Freitag, H., et al., Autoantibodies to Vasoregulative G-Protein-Coupled Receptors Correlate489with Symptom Severity, Autonomic Dysfunction and Disability in Myalgic490Encephalomyelitis/Chronic Fatigue Syndrome. J Clin Med, 2021. 10(16).
- 491 15. Bynke, A., et al., Autoantibodies to beta-adrenergic and muscarinic cholinergic receptors in
 492 Myalgic Encephalomyelitis (ME) patients A validation study in plasma and cerebrospinal fluid
 493 from two Swedish cohorts. Brain Behav Immun Health, 2020. 7: p. 100107.
- 494 16. Sotzny, F., et al., *Dysregulated autoantibodies targeting vaso- and immunoregulatory*495 *receptors in Post COVID Syndrome correlate with symptom severity.* Front Immunol, 2022. 13:
 496 p. 981532.
- 49717.Merad, M. and J.C. Martin, Author Correction: Pathological inflammation in patients with498COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol, 2020. 20(7): p. 448.
- 499 18. Ye, Q., B. Wang, and J. Mao, *The pathogenesis and treatment of the `Cytokine Storm' in COVID-*500 19. J Infect, 2020. **80**(6): p. 607-613.
- Hu, W.T., et al., *Clinical and CSF single-cell profiling of post-COVID-19 cognitive impairment*.
 Cell Rep Med, 2024. 5(5): p. 101561.
- Bell, D.S., *The Doctor's Guide To Chronic Fatigue Syndrome: Understanding, Treating, And Living* With Cfids. 1994: Da Capo Press.
- 505 21. Cotler, J., et al., A Brief Questionnaire to Assess Post-Exertional Malaise. Diagnostics (Basel),
 506 2018. 8(3).

All rights reserved. No reuse allowed without permission.

- Cella, M. and T. Chalder, *Measuring fatigue in clinical and community settings*. J Psychosom Res, 2010. **69**(1): p. 17-22.
 Sletten, D.M., et al., *COMPASS 31: a refined and abbreviated Composite Autonomic Symptom Score*. Mayo Clin Proc, 2012. **87**(12): p. 1196-201.
 Harris, P.A., et al., *Research electronic data capture (REDCap)--a metadata-driven*
- 512 *methodology and workflow process for providing translational research informatics support.* J 513 Biomed Inform, 2009. **42**(2): p. 377-81.
- 51425.Harris, P.A., et al., The REDCap consortium: Building an international community of software515platform partners. J Biomed Inform, 2019. **95**: p. 103208.
- 51626.Ravensberg, A.J., et al., Eotaxin-2 and eotaxin-3 expression is associated with persistent517eosinophilic bronchial inflammation in patients with asthma after allergen challenge. J Allergy518Clin Immunol, 2005. 115(4): p. 779-85.
- Son, J.W., et al., *Glia-Like Cells from Late-Passage Human MSCs Protect Against Ischemic Stroke Through IGFBP-4*. Mol Neurobiol, 2019. 56(11): p. 7617-7630.
- 52128.Scott, X.O., et al., Cohort study on the differential expression of inflammatory and angiogenic522factors in thrombi, cerebral and peripheral plasma following acute large vessel occlusion523stroke. J Cereb Blood Flow Metab, 2022. **42**(10): p. 1827-1839.
- 52429.Mahdi, A., et al., Dysregulations in hemostasis, metabolism, immune response, and525angiogenesis in post-acute COVID-19 syndrome with and without postural orthostatic526tachycardia syndrome: a multi-omic profiling study. Scientific Reports, 2023. 13(1): p. 20230.

30. Wang, J., et al., *Pathogenesis of allergic diseases and implications for therapeutic interventions*.
Signal Transduct Target Ther, 2023. 8(1): p. 138.

- S1. Vargas-Leal, V., et al., *Expression and function of glial cell line-derived neurotrophic factor family ligands and their receptors on human immune cells.* J Immunol, 2005. **175**(4): p. 23018.
- 53232.Mielcarska, S., et al., Assessment of the RANTES Level Correlation and Selected Inflammatory533and Pro-Angiogenic Molecules Evaluation of Their Influence on CRC Clinical Features: A534Preliminary Observational Study. Medicina (Kaunas), 2022. 58(2).
- S35 33. Ryan, F.J., et al., Long-term perturbation of the peripheral immune system months after SARSS36 CoV-2 infection. BMC Med, 2022. 20(1): p. 26.
- 53734.Xue, S., et al., C-C motif ligand 8 promotes atherosclerosis via NADPH oxidase 2/reactive538oxygen species-induced endothelial permeability increase. Free Radical Biology and Medicine,5392021. 167: p. 181-192.
- 54035.Kawakami, A., N. Iwamoto, and K. Fujio, *Editorial: The role of monocytes/macrophages in*541autoimmunity and autoinflammation. Front Immunol, 2022. **13**: p. 1093430.

54236.Melo, A.K.G., et al., Biomarkers of cytokine storm as red flags for severe and fatal COVID-19543cases: A living systematic review and meta-analysis. PLoS One, 2021. 16(6): p. e0253894.

- 54437.Giloteaux, L., et al., Proteomics and cytokine analyses distinguish myalgic545encephalomyelitis/chronic fatigue syndrome cases from controls. Journal of Translational546Medicine, 2023. **21**(1): p. 322.
- S47 38. Corbitt, M., et al., A systematic review of cytokines in chronic fatigue syndrome/myalgic
 s48 encephalomyelitis/systemic exertion intolerance disease (CFS/ME/SEID). BMC Neurology,
 s49 2019. 19(1): p. 207.
- 55039.Bekbossynova, M., et al., Unraveling Acute and Post-COVID Cytokine Patterns to Anticipate551Future Challenges. Journal of Clinical Medicine, 2023. 12(16): p. 5224.
- 40. Moneghetti, K.J., et al., *Value of Circulating Cytokine Profiling During Submaximal Exercise Testing in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome*. Scientific Reports, 2018. 8(1):
 p. 2779.
- 555 41. Sfera, A., et al., *Microbial Translocation Disorders: Assigning an Etiology to Idiopathic Illnesses.*556 Applied Microbiology, 2023. 3(1): p. 212-240.
- Landers-Ramos, R.Q., et al., *Circulating angiogenic and inflammatory cytokine responses to acute aerobic exercise in trained and sedentary young men.* European Journal of Applied
 Physiology, 2014. **114**(7): p. 1377-1384.

All rights reserved. No reuse allowed without permission.

- Gleissner, C.A., P. von Hundelshausen, and K. Ley, *Platelet chemokines in vascular disease*.
 Arterioscler Thromb Vasc Biol, 2008. 28(11): p. 1920-7.
- Furuta, A., et al., *Time-dependent changes in bladder function and plantar sensitivity in a rat model of fibromyalgia syndrome induced by hydrochloric acid injection into the gluteus.* BJU
 Int, 2012. **109**(2): p. 306-10.
- 565 45. Bohmwald, K., et al. *Neurotrophin Signaling Impairment by Viral Infections in the Central*566 *Nervous System*. International Journal of Molecular Sciences, 2022. 23, DOI:
 567 10.3390/ijms23105817.
- 568 46. Blundell, S., et al., *Chronic fatigue syndrome and circulating cytokines: A systematic review.*569 Brain Behav Immun, 2015. **50**: p. 186-195.
- 57047.Petri, R.M., et al., Activated Tissue-Resident Mesenchymal Stromal Cells Regulate Natural Killer571Cell Immune and Tissue-Regenerative Function. Stem Cell Reports, 2017. 9(3): p. 985-998.
- 48. Angelosanto, J.M., et al., *Progressive loss of memory T cell potential and commitment to exhaustion during chronic viral infection.* J Virol, 2012. **86**(15): p. 8161-70.
- 49. Gao, Z., et al., *T-cell exhaustion in immune-mediated inflammatory diseases: New implications* for immunotherapy. Front Immunol, 2022. **13**: p. 977394.
- 57650.Heming, M., et al., Neurological Manifestations of COVID-19 Feature T Cell Exhaustion and577Dedifferentiated Monocytes in Cerebrospinal Fluid. Immunity, 2021. 54(1): p. 164-175.e6.
- 57851.Fagiolo, E. and C.T. Terenzi, Enhanced IL-10 Production In Vitro by Monocytes in Autoimmune579Haemolytic Anaemia. Immunological Investigations, 1999. 28(5-6): p. 347-352.
- 580
- 581

582 Funding

- 583 Founded by BMBF (German ministry for education and research) project "Elucidating the
- immune pathomechanisms of post-infectious ME/CFS (IMMME), funding number 01EJ2204C.
- 585

586 Acknowledgments

- 587 We are grateful to the patients who participated in this study despite their individual disease 588 related impairment.
- 589

590 Conflict of interest

591 The authors GR and AH hold a submitted patent for cytokine signature detecting Post-COVID 592 Syndrome, signatures for Post-COVID Syndrome with or without ME/CFS, respectively. The 593 authors declare that HH and KS-F are managing directors of CellTrend. CellTrend holds 594 together with Charité a patent for the diagnostic use of AABs against ADRB2. CS has a 595 consulting agreement with CellTrend. The remaining authors declare that the research was 596 conducted in the absence of any commercial or financial 597 as a potential conflict of interest.

598 Table and figure Legends

- Table 1. Clinical scorings and cohort characterization. Continuous variables were expressed
 as median and range. Univariate comparisons of study groups were done using the Kruskal–
 Wallis test (three groups) or the Mann-Whitney-U-Test (two groups). A two-tailed p-value of
 <0.01 was considered statistically significant. [n. a. = not assessed].
- Figure 1. Identification of IgG-induced monocytic secretome in PCS patients compared to HC.
 PCA analysis indicated that the two cohorts are distinct based on monocytic secretome
 between PCS patients and HC (A) and between nPCS and pcME/CFS (B). The heatmap
 revealed an association between spike or NCAP IgGs and secretome factors between nPCS,
 pcME/CFS, and HC (C).
- Figure 2. Exploration of cytokine expression between different groups: pcME/CFS&nPCS vs.
 HC (A), pcME/CFS vs. PCS (B), nPCS vs. HC (C), and pcME/CFS vs. HC (D). The volcano
 plot illustrates differences in cytokine expression between the groups after stimulation of
 monocytic cells with IgG.
- Figure 3. Correlations between cytokines and major signaling pathways in AAB-induced 612 monocyte secretome in HC (A), PCS (B), and pcME/CFS (C). The nodes in the graphs (A, C, 613 and E) represent variables (each cytokine), and a line between two nodes indicates 614 Spearman's rank correlation coefficient. The line width indicates the strength of the 615 association, with stronger correlations indicated by thicker lines. Multiple connections of nodes 616 indicate clustering between the variables. The bar plot (B, D, and F) indicates the 10 most 617 representative altered canonical KEGG pathways affected by the differentially expressed 618 cytokines. The most significantly enriched pathways are depicted in a progressively redder 619 620 colour.
- Figure 4. The heat map of the correlation matrix summarizes the results of Spearman correlation analysis among the clinical symptom scores and cytokine data considered in PCS (A) and pcME/CFS (B). Spearman correlation coefficients (r) are indicated in the relative boxes at the intersection between the considered variables. Positive and negative correlation coefficients are shown in red and blue, respectively.
- 626
- 627
- 628
- 629
- 630

Figure 1



Figure 2





C nPCS vs. HC





D pcME/CFS vs. HC







Figure 3













649

650

Figure 4



A nPCS Cytokine Correlations with Clinical Scores

B pcMECFS Cytokine Correlations with Clinical Scores



652

653